Australian analytics company Max Kelsen is using artificial intelligence (AI) to predict the effectiveness of cancer treatments.
The company is integrating AI and whole-genome sequencing into cancer research and clinical practice, focusing initially on immunotherapy treatment for melanoma and small cell lung cancer.
One in four Australians are diagnosed with cancer in their lifetime, and while immunotherapy has shown great promise for improving patient survival across a variety of cancer types, including melanoma and lung cancer, it isn’t guaranteed to be effective for all patients — only 40-42 percent of people will respond effectively.
